Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Rheumatol. 1995 Jan;22(1):41-4.

Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months.

Author information

  • 1Department of Medicine, Albany Medical College, NY 12208.

Abstract

OBJECTIVE:

To compare pharmacokinetic variables of a 7.5 mg dose of MTX in a cohort of patients with rheumatoid arthritis (RA) beginning therapy with the drug with a cohort of patients receiving the drug for a mean period of 81 months.

METHODS:

Standard pharmacokinetic measures were performed in 35 patients beginning MTX therapy and 15 patients who had received the drug for a mean of 81 months.

RESULTS:

No significant differences in area under the serum concentration versus time curve (AUC), maximal methotrexate concentration following dosing (Cmax), time to Cmax (Tmax), bioavailability (F), urinary MTX, renal clearance of MTX or creatinine clearance were observed between the 2 cohorts.

CONCLUSION:

We were unable to demonstrate significant differences in pharmacokinetic variables in these cohorts with a 7.5 mg standard dose of MTX. It is possible that a difference may exist when a standard higher dose of MTX is compared in these types of patients.

PMID:
7699679
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk